The Dow Jones Industrial average jumped about 125 points on Monday but has given back about two-thirds of that gain through trading so far today. The story with the S&P 500 index is similar, though not quite so severe: a giveback of about a quarter of Monday's gain. The NASDAQ Composite index is doing better, up about 3% so far today, to remain virtually even with Monday's gains. The indices are slowly gaining back some ground lost earlier this morning, so by the close of trading today, the markets could show a small gain.

Here are the numbers:

Dow 9,712.28 -29.92 (-0.31%)
S&P 500 1,057.07 -3.54 (-0.33%)
Nasdaq 2,122.42 -1.62 (-0.08%)

Some days you know you have a winner, and some days you know you have a loser. Just like the loss of 473,000 jobs to 9.5% unemployment in June, today started as a losing day and ended up as a losing day. It feels as though the "lagging indicator" aspect of employment may lead us into a new leg-down in the recession. At least there was some bit of good news: bond yields came down.

Here were today's closing bell levels:

Dow 8,306.21 -197.85 (-2.33%)
S&P 500 898.88 -24.45 (-2.65%)
Nasdaq 1,798.12 -47.60 (-2.58%)

Top Analyst Upgrades and Downgrades

Monday, April 28

• PDUFA date for Genentech, Inc. (NYSE: DNA) and Roche Holding Ltd. (OTC: RHHBY)'s supplemental Biologics License Application for Herceptin for label expansion to include AC followed by docetaxel in treatment of adjuvant HER2+ breast cancer.
• PDUFA date for Shire plc (NASDAQ: SHPGY) and New River Pharma's supplemental New Drug Application for Vyvanse (NRP-104) treatment of Attention Deficit Hyperactivity Disordre, or ADHD, in adult patients 18-55 years old; the drug is already approved for pediatric ADHD ages 6-12.
• Verizon Communications Inc. (NYSE: VZ) to report Q earnings; conference call at 8:30am.
• Tyson Foods, Inc. (NYSE: TSN) to report Q2 earnings; conference call at 9:00am.

Tuesday, April 29

• Two-day FOMC meeting beginning at 8:30am.
• PDUFA date for Merck & Co., Inc. (NYSE: MRK)'s New Drug Application for Cordaptive (MK-0524A) adjunctive therapy to diet for treating elevated LDL Cholesterol, low HDL Cholesterol and elevated triglycerides levels.
  
• PDUFA date for Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP)'s supplemental New Drug Application for dose of 8mg treatment of Irritable Bowel Syndrome with Constipation; already approved for Chronic Idiopathic Constipation at 24ug dosage.
• BP plc (NYSE: BP) to report Q1 earnings; conference call at 10:15am.
• United States Steel Company (NYSE: X) to report Q1 earnings; conference call at 2:00pm.